Search results for #TH2
bit.ly/3PCsbop - Read the Article here A Review Emphasis on Imbalance of Th1/Th2 Cytokines in The Progression of Diabetes to Diabetic Related Complications #Diabetes #Diabeticnephropathy #Diabeticretinopathy #T1DM #T2DM #Th1 #Th2 #cytokines #chemistry #biochemistry
$CRVS #soquelitinib Ph1 trial for atopic dermatitis w/ upstream MoA that stops #ILC2, #Th2, #Th17. If successful, major AD drugs worth Billions at risk: $SNY $REGN Dupilumab $GSK Mepolizumab $AZN Benralizumab $PFE Fezakinumabn $NVS Omalizumab Ligelizumab x.com/conradenge9805…
$CRVS #soquelitinib Ph1 trial for atopic dermatitis w/ upstream MoA that stops #ILC2, #Th2, #Th17. If successful, major AD drugs worth Billions at risk: $SNY $REGN Dupilumab $GSK Mepolizumab $AZN Benralizumab $PFE Fezakinumabn $NVS Omalizumab Ligelizumab x.com/conradenge9805… https://t.co/DXpBunhJ8s
Atopic Dermatitis (AD) fast growing autoimmune market, proj to double in 10 years >$30B. $CRVS ITK inhibitor #soquelitinib started Ph 1 AD trial. Unique upstream approach knocks out #Th2, #Th17 and #ILC2 cells and downstream cytokines that takes 8 other AD drugs to do separately
$CRVS oral ITK inhibitor #soquelitinib in Ph1 atopic dermatitis trial Knocks out #Th2, #Th17 and #ILC2 cells, stopping cytokines (IL-4/5/13). Novel upstream approach reduces multiple inflammation pathways at once, that takes ~8 AD drugs to do now $SNY $REGN $GSK $AZN $LLY $PFE
If chance of success is 50% just for atopic dermatitis indication x $CRVS $500M-$1B MC, $10-$20sh (value if data good) = current MC should be ~$250M-$500M, $5-$10/sh Stock at $1.40. Data more supportive of success as soquelitinib reduces #Th2, lowers IL-13 and TARC!
If chance of success is 50% just for atopic dermatitis indication x $CRVS $500M-$1B MC, $10-$20sh (value if data good) = current MC should be ~$250M-$500M, $5-$10/sh Stock at $1.40. Data more supportive of success as soquelitinib reduces #Th2, lowers IL-13 and TARC!
Today’s #JEMLegacy goes back to 1989. A study by Tim Mosmann & colleagues marks the discovery of #IL10. It was first described as cytokine synthesis inhibitory factor (CSIF) that was produced by #Th2 cells and inhibited cytokine production by #Th1 cells. doi.org/10.1084/jem.17…
$CRVS skews for #Th1 cells while shutting off #Th2 and #Th17 and downstream cytokines. How? Does increasing #soquelitinib ITKi dose reduces Ca2+ in hierarchical fashion via calcineurin/NFAT? First OFF is Th2 w/ lowest Ca2+ Then Th17 Th1 last 2nd/3rd gen! journals.aai.org/jimmunol/artic…
$APGE up 35% or $700M for #atopicdermatitis studies to $3B MC! Goal: lower Th2 and IL-13 for auto-immune via its monoclonal AB injections $CRVS oral Soquelitinib already (1) halts #Th2 prod, (2) LOWERS IL-13, (3) cured 5 dogs of AD, Mar Cap $110M? $CRVS kicking off AD trial
$APGE up 35% or $700M for #atopicdermatitis studies to $3B MC! Goal: lower Th2 and IL-13 for auto-immune via its monoclonal AB injections $CRVS oral Soquelitinib already (1) halts #Th2 prod, (2) LOWERS IL-13, (3) cured 5 dogs of AD, Mar Cap $110M? $CRVS kicking off AD trial
@FrontImmunol $CRVS ITK inhibitor #soquelitinib is the way to make better tumor micro environment (TME) for therapies: - increases IFN-γ and #Th1 - migrates CD8+ cells to and infiltrate tumor - increases memory T-cells (TEMRA) - stops #Th2 cells (IL-4, IL-13) - reduces CD4+ Treg in tumor
@AQUAPLUS_JP 『ToHeart2ダンジョントラベラーズ』 フォロー&リポストキャンペーン開催🎉ありがとうございます㊗ヽ(´ー`)ノ👏🎊🙇 Steam版がもらえちゃうなんて嬉しいプレゼント🎁🎉ですねぇ🤗 ぜひともご縁を頂いて、お迎えしたいです(*´艸`*)🎶 #ダントラ #TH2
$CRVS focused on ITK inhibitor #soquelitinib: P3 PTCL, P1b/2 RCC solid tumor, autoimmune, atopic dermatitis in '24 + partnership interest #Th2, #Th17 selective 2nd/3rd gen ITKi more diseases include: adipose tissue - #obesity, #InsulinResistance liver tissue - #NAFLD, #NASH
@JessieChimni $CRVS oral ITK inhibitor approach to modulating and turning off production of #Th2 and #Th17 cells upstream for #autoimmune has rapidly expanded their TAM as well.
@JessieChimni $CRVS oral ITK inhibitor approach to modulating and turning off production of #Th2 and #Th17 cells upstream for #autoimmune has rapidly expanded their TAM as well.